Skip to content

CFDs are complex financial instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money. CFDs are complex financial instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.

GlaxoSmithKline (LON:GSK) share price: what to expect from its Q1 results

The pharmaceutical company recorded a strong 2018, with the company wasting no time in driving growth this year with investors eager for an update on its acquisition of Tesaro and its consumer health joint venture with Pfizer.

GlaxoSmithKline GSK Source: Bloomberg

When is GlaxoSmithKline’s results date?

GlaxoSmithKline (GSK) will release its Q1 trading update on May 1.

GlaxoSmithKline results preview: what does the city expect?

At the end of what was a very successful 2018, GSK announced it would form a new world-leading consumer healthcare joint venture (JV) with rival Pfizer in a move that will see its combined businesses generate sales of around £9.8 billion.

Under the terms of the deal, GSK controls a 68% majority stake in the JV, with the transaction representing a major opportunity for the pharmaceutical company to build on its recent buyout of Novartis that will help it deliver significant shareholder value.

Investors will welcome an update on the JV, which brings together two highly complementary portfolios of consumer health brands, including GSK’s Sensodyne, Voltaren, and Panadol, alongside Pfizer’s Advil, Centrum and Caltrate.

The deal will also see the newly formed business become a global leader I over-the-counter products with a market share of 7.3% ahead of its nearest rival and allow it to grab the number one or two position in all major geographies, including the US and China. Overall the Joint Venture will target an Adjusted operating margin percentage in the ‘mid-to-high 20’s’ by 2022.

Investors will have their eye on what GSK intends to pay in dividends to shareholders for 2019, with the JV allowing them to confirm an 80p a share payout, which its management intends to maintain.

In January, GSK completed its acquisition of oncology focused biopharmaceutical company Tesaro in a deal valued at £4 billion that will strengthen its pharmaceutical business, accelerating the build of GSK’s pipeline and commercial capability in oncology.

‘The acquisition of Tesaro, which we have completed today, significantly strengthens our oncology pipeline and brings new scientific capabilities and expertise that will increase the pace and scale at which we can help patients living with cancer,’ GSK Chief Scientific Officer and President Dr Hal Barron said.

Overall, investors are expecting another strong year from GSK, with analysts arguing that the stock is undervalued. Zacks Equity Research gave the stock a ‘Buy’ rating, pointing to the fact that GSK is trading with price/earnings (P/E) ratio of 13.51, compared to an industry average of 14.37. Over the past 52 weeks, GSK’s forward P/E has hit as high as 14.65 and as low as 12.29, with a median of 13.59.


This information has been prepared by IG, a trading name of IG Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
CFDs are a leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your initial deposit, so please ensure that you fully understand the risks involved.

Be ready to act on ECB opportunities

Learn how the ECB’s monetary policy announcements affect interest rates and price stability ahead of its next meeting in 30 January 2025.

  • How might the next meeting affect the markets?
  • What are the key rate decisions to watch?
  • Why is the Governing Council announcement important for traders?

Live prices on most popular markets

  • Forex
  • Shares
  • Indices

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

Plan your trading week

Get the week’s market-moving news sent directly to your inbox every Friday. The Week Ahead gives you a full calendar of upcoming economic events, as well as commentary from our expert analysts on the key markets to watch.

For more info on how we might use your data, see our privacy notice and access policy and privacy webpage.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.